Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine
BJPsych Advances · 2023-03 · 29 (2) · 145-150
DOI: 10.1192/bja.2021.49 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych Advances, online erschienen am 02.09.2021. Verfasst von John Cookson und 1 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Aripiprazole, brexpiprazole and cariprazine are partial dopamine (and serotonin) agonists developed as novel antipsychotics. This article discusses their pharmacology, evidence on their licensed and off-licence uses (including psychosis, mania, bipolar depression, Tourette syndrome and autism spectrum disorder) and side-effects. In schizophrenia, they have a low risk of Parkinsonism or hyperprolactinaemia, cause modest increases in body weight and are of moderate efficacy.
Zitieren
APA
Cookson, J., & Pimm, J. (2023). Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. BJPsych Advances, 29(2), 145-150. https://doi.org/10.1192/bja.2021.49
Vancouver
Cookson J, Pimm J. Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. BJPsych Advances. 2023;29(2):145-150. doi:10.1192/bja.2021.49
BibTeX
@article{Cookson2023,
author = {Cookson, John and Pimm, Jonathan},
title = {Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine},
journal = {BJPsych Advances},
year = {2023},
volume = {29},
number = {2},
pages = {145--150},
doi = {10.1192/bja.2021.49}
}
EUVIMED